As of January 1, 2019, Hawaii State Medicaid (MedQUEST) has removed requirements on fibrosis and sobriety in its guidance for hepatitis C medications. This is in alignment with recommendations from the American Association for the Study of Liver Diseases, and it will provide more people access to life-saving treatment.
We will continue to work with patients, providers, and insurance plans to ensure that these new recommendations are implemented. Please contact us if you would like to report any issues with access.
For more clinician resources, click here.